Status: Recruiting
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extension phase, where available, in which all subjects will receive Halneuron.
Participants needed: 240
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Dogwood Therapeutics Inc.Updated: May 29, 2026Locations: 25
Eligibility criteria
Male or female patients aged ≥18 years. [+2]
Current neuropathic pain with symptoms similar to CINP but attributed to causes... [+1]